Bio-Rad Laboratories, Inc. (BIO) Receives $273.33 Consensus Price Target from Brokerages
Bio-Rad Laboratories, Inc. (NYSE:BIO) has earned an average rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $277.75.
A number of research analysts recently issued reports on BIO shares. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a report on Monday, November 13th. Deutsche Bank restated a “buy” rating and set a $255.00 price target on shares of Bio-Rad Laboratories in a report on Monday, September 18th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $290.00 price target (up previously from $250.00) on shares of Bio-Rad Laboratories in a report on Wednesday, November 29th.
In other Bio-Rad Laboratories news, EVP Giovanni Magni sold 2,400 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $253.01, for a total transaction of $607,224.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $2,340,595.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP James R. Stark sold 746 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $270.51, for a total value of $201,800.46. The disclosure for this sale can be found here. Insiders have sold a total of 4,146 shares of company stock worth $1,067,414 in the last quarter. Company insiders own 28.29% of the company’s stock.
Shares of Bio-Rad Laboratories (BIO) traded up $0.17 during trading hours on Friday, reaching $253.35. The company had a trading volume of 180,400 shares, compared to its average volume of 179,499. Bio-Rad Laboratories has a 52 week low of $177.68 and a 52 week high of $273.87. The stock has a market cap of $7,535.40, a P/E ratio of 80.38, a PEG ratio of 3.78 and a beta of 0.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.77 and a current ratio of 4.06.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.37. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The company had revenue of $535.00 million for the quarter, compared to the consensus estimate of $507.99 million. During the same quarter in the previous year, the business earned $0.62 EPS. Bio-Rad Laboratories’s revenue was up 5.2% compared to the same quarter last year. equities research analysts anticipate that Bio-Rad Laboratories will post 2.68 earnings per share for the current fiscal year.
Bio-Rad Laboratories declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 28th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Stock Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related stocks with our FREE daily email newsletter.